Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 27.95 PB Ratio: 2.13 GF Score: 49/100

Biogen Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2020 / 02:30PM GMT
Release Date Price: ARS2800 (+4.79%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. I'm pleased to have Biogen with me for the next session.

Just briefly before we get started, I need to read a quick disclosure statement. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you're a member of the press, please disconnect and reach out separately. For important disclosures, please see Morgan Stanley research disclosures website at morganstanley.com/researchdisclosures, and reach out to your Morgan Stanley sales rep, if you need anything.

So with me, I have Michel Vounatsos, who's the CEO; as well as Mike McDonnell, who is the new CFO. And Michel, I'm going to turn it over to you for some opening remarks, and then we will get started.

Michel Vounatsos
Biogen Inc. - CEO & Director

Thank you, Matthew.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot